Pfizer Inc. $PFE Shares Acquired by JT Stratford LLC

JT Stratford LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 301.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 70,370 shares of the biopharmaceutical company’s stock after buying an additional 52,849 shares during the period. JT Stratford LLC’s holdings in Pfizer were worth $1,793,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the company. Grey Fox Wealth Advisors LLC acquired a new stake in Pfizer during the 3rd quarter worth about $29,000. Howard Hughes Medical Institute acquired a new stake in shares of Pfizer during the second quarter worth about $30,000. Darwin Wealth Management LLC purchased a new stake in Pfizer in the second quarter valued at approximately $32,000. Evelyn Partners Asset Management Ltd acquired a new position in Pfizer in the 2nd quarter worth approximately $33,000. Finally, True Wealth Design LLC raised its position in Pfizer by 302.5% during the 3rd quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 974 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

PFE has been the topic of several recent research reports. Daiwa Securities Group downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective on the stock. in a report on Thursday, February 12th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. Scotiabank initiated coverage on Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price target on the stock. Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price objective for the company in a report on Monday. Finally, TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a report on Tuesday, December 30th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $28.05.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Argus raised Pfizer to a “Buy,” giving the stock near‑term analyst momentum that can attract flows. Pfizer (NYSE:PFE) Raised to “Buy” at Argus
• Positive Sentiment: Pfizer reported progress on PF‑07328948 (kidney function) Phase 1 work — a pipeline advancement that supports longer‑term product value and upside beyond current franchises. Pfizer Advances PF-07328948 Kidney Function Study, Supporting Long-Term Pipeline Value
• Positive Sentiment: Oncology milestones (PADCEV+Keytruda Phase 3 benefits and full FDA approval for a BRAFTOVI regimen) reshape growth prospects away from COVID‑era revenues — a material strategic positive for future revenue mix. Pfizer Oncology Milestones Reshape Outlook Beyond COVID 19 Revenues
• Positive Sentiment: Telescope Innovations installed a second self‑driving lab at Pfizer — a tangible move toward Physical AI and factory automation that could improve throughput, quality, and costs over time. Telescope Innovations Installs Second Self-Driving Lab at Pfizer, Advancing Physical AI Deployment
• Positive Sentiment: Market commentary continues to frame Pfizer as a defensive, high‑yield option (dividend yield cited as attractive), which supports demand in risk‑off environments. The Dividend Safe Harbor: 2 Stocks to Watch (PFE)
• Positive Sentiment: Analyst/market pieces highlight improving cash generation and active portfolio renewal, reinforcing a recovery narrative that could boost multiple expansion if sustained. Pfizer’s Quiet Cash Comeback Pfizer’s Portfolio Renewal In Progress – High Yields For The Patient
• Neutral Sentiment: Consensus analyst rating remains a “Hold” per a recent roundup — a signal that while sentiment is improving, broad analyst conviction is not yet uniformly bullish. Pfizer Inc. (NYSE:PFE) Receives Consensus Rating of “Hold” from Analysts
• Neutral Sentiment: Industry reports on AI in pharma manufacturing note Pfizer among large firms integrating AI — a positive trend but more structural and longer‑term than an immediate earnings driver. AI in Pharma Manufacturing Market Research 2026-2040
• Neutral Sentiment: NYSE floor events (bell‑ringing notices) are routine market color without company‑specific impact. NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals

Pfizer Stock Performance

Shares of Pfizer stock opened at $26.61 on Thursday. The company has a quick ratio of 0.87, a current ratio of 1.16 and a debt-to-equity ratio of 0.71. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.94. The firm’s 50 day moving average is $26.23 and its two-hundred day moving average is $25.45. The firm has a market capitalization of $151.31 billion, a P/E ratio of 19.57 and a beta of 0.47.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.63 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.5%. Pfizer’s dividend payout ratio (DPR) is presently 126.47%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.